We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

3 hedge funds and large institutions have $458K invested in VanEck Vectors Generic Drugs ETF in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

25% less funds holding

Funds holding: 4 → 3 (-1)

35% less capital invested

Capital invested by funds: $703K → $458K (-$245K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$10K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$202K
2
IA
IFP Advisors
Florida
-$51K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$354K -$202K -8,970 -36%
UBS Group
2
UBS Group
Switzerland
$78K +$10K +445 +15%
FDCDDQ
3
Federation des caisses Desjardins du Quebec
Quebec, Canada
$25.9K – – –
IA
4
IFP Advisors
Florida
– -$51K -2,250 Closed

GNRX Hedge Fund Activity: Q2 2017 in Review

3 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q2 2017, worth a combined $458K — down 35% from $703K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GNRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $10K. The largest seller was Citadel Advisors, cutting an estimated $202K.

  • 3 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q2 2017, down from 4 in Q1 2017.
  • Funds reported $458K of VanEck Vectors Generic Drugs ETF stock for Q2 2017, down 35% quarter-over-quarter.
  • 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q2 2017 and 1 closed out, a net change of -1 holder.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q2 2017 was UBS Group, an estimated $10K added.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q2 2017 was Citadel Advisors, an estimated $202K sold.

Based on aggregated 13F filings for Q2 2017.